DDO-6600
Based on 1 Customer Validation
DDO-6600 is a covalent Hsp90α inhibitor. DDO-6600 allosterically disrupts the Hsp90-Cdc37 interaction. DDO-6600 promotes Apoptosis and the degradation of Cdc37-dependent kinase client proteins (Cdc37-dependent kinase client proteins include AKT and CDK4). DDO-6600 can be used in research on colon cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.19%
- CAS No.: 2640292-37-9
- Formule: C26H28N4O2
- Masse moléculaire:428.53
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[3]|
HSP90α |
Akt |
CDK4 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
7.83 μM
|
Antiproliferative activity against human HCT-116 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
Antiproliferative activity against human HCT-116 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
|
40310691 |
| HCT-116 | IC50 |
25.06 μM
|
Antiproliferative activity against Cdc37-knockout HCT-116 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
Antiproliferative activity against Cdc37-knockout HCT-116 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
|
40310691 |
| HT-29 | IC50 |
10.21 μM
|
Antiproliferative activity against human HT-29 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
Antiproliferative activity against human HT-29 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
|
40310691 |
| SK-BR-3 | IC50 |
13.92 μM
|
Antiproliferative activity against human SKBR-3 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
Antiproliferative activity against human SKBR-3 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
|
40310691 |
| MCF7 | IC50 |
12.17 μM
|
Antiproliferative activity against human MCF-7 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
Antiproliferative activity against human MCF-7 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
|
40310691 |
| HT-1080 | IC50 |
14.77 μM
|
Antiproliferative activity against human HT-1080 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
Antiproliferative activity against human HT-1080 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
|
40310691 |
| CT26 | IC50 |
9.24 μM
|
Antiproliferative activity against mouse CT-26 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
Antiproliferative activity against mouse CT-26 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.
|
40310691 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude (female, 6 weeks old)[3]
-
Dosage:30 mg/kg
-
Administration:intraperitoneal; every 2 days; 14 days
-
Result:DDO-6691 reduced tumor volume relative to vehicle by day 26.
DDO-6691 decreased CDK4 and did not increase Hsp90 or Hsp70.
Chemical Information
-
CAS No. 2640292-37-9
-
Appearance Solid
-
Masse moléculaire 428.53
-
Formule C26H28N4O2
-
Color White to off-white
-
SMILES
O=C(N1C(CCCC1)C(N)=O)/C=C/C2=CN(C3=CC=CC=C3)N=C2C4=CC(C)=C(C=C4)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[2]. Liu Y, et al. Targeted Covalent Inhibition: A Prospective Way to Develop Novel HSP90 C-terminal Inhibitor. Current Drug Targets. 2022 Dec 1;23(16):1454-6. [Content Brief]
[3]. Feng ZW, et al. Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity. Journal of medicinal chemistry. 2025 May 22;68(10):9886-9905. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DDO-6600 Related Classifications
HY-147125 Related Classifications
Powered by Bioz